Endocarditis Management Guidelines

Diagnostic Approach

• The European Society of Cardiology recommends obtaining three sets of blood cultures at 30-minute intervals before initiating antibiotics to maximize pathogen identification 3, 4
• Consider blood culture-negative infective endocarditis (BCNIE) when initial cultures are negative, and extend antibiotic spectrum to cover potential pathogens like Brucella, C. burnetii, and Bartonella 3, 5
• Consult with an infectious disease specialist for BCNIE cases to guide appropriate diagnostic workup and treatment 4

Antimicrobial Therapy

• The European Heart Society recommends starting empiric therapy promptly after blood cultures are drawn 3
• Consider key factors when selecting empiric regimens, including previous antibiotic exposure 4, native versus prosthetic valve involvement 1, setting of infection (community-acquired vs. healthcare-associated) 6, and local epidemiology and resistance patterns 3, 4
• For native valve endocarditis (NVE), empiric regimens should cover staphylococci, streptococci, and enterococci 1
• For early prosthetic valve endocarditis (PVE), cover methicillin-resistant staphylococci, enterococci, and non-HACEK gram-negative pathogens 1, 6
• Adjust antimicrobial therapy once the pathogen is identified (usually within 48 hours) based on susceptibility testing 1, 6
• For streptococcal endocarditis, use penicillin, ceftriaxone, or vancomycin (for penicillin-allergic patients) 7
• For enterococcal endocarditis, use combination therapy with penicillin/ampicillin plus gentamicin; vancomycin for resistant strains 3, 7
• For staphylococcal native valve endocarditis, use nafcillin, oxacillin, or cefazolin for methicillin-susceptible strains; vancomycin for methicillin-resistant strains 7
• For staphylococcal prosthetic valve endocarditis, use combination therapy with rifampin, gentamicin, and either nafcillin/oxacillin or vancomycin based on methicillin susceptibility 7, 8
• For HACEK organisms, use ceftriaxone for 4 weeks in NVE and 6 weeks in PVE 5, 9
• For non-HACEK gram-negative bacteria, use early surgery plus long-term therapy (at least 6 weeks) with bactericidal combinations of beta-lactams and aminoglycosides 10
• For fungal endocarditis, use combined antifungal therapy and surgical valve replacement due to high mortality (>50%) 4, 9

Duration of Therapy

• The standard duration is 4-6 weeks of parenteral therapy to prevent treatment failure or relapse 1, 2
• Monitoring of antibiotic levels (particularly for vancomycin and aminoglycosides) is essential 1, 2

Outpatient Parenteral Antibiotic Therapy (OPAT)

• Two phases of antibiotic therapy should be considered: critical phase (first 2 weeks) and continuation phase (beyond 2 weeks) 6, 8
• Consider OPAT only for stable patients with uncomplicated infections (oral streptococci or S. bovis, native valve) 6, 8
• Avoid OPAT in patients with heart failure, concerning echocardiographic features, neurological signs, or renal impairment 6, 8
• Essential OPAT requirements include patient/staff education, regular post-discharge evaluation, and physician-directed program 6, 8

Surgical Management

• Approximately 50% of endocarditis patients require surgical intervention 2, 8
• Early consultation with cardiac surgery is recommended to determine optimal approach 2, 8
• Main indications for surgery include heart failure due to valve dysfunction 8, uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation) 8, prevention of systemic embolism 8, fungal or multiresistant organism infections 8, and persistent positive blood cultures despite appropriate antibiotic therapy 8

Multidisciplinary Approach

• Management by an "Endocarditis Team" is recommended, including infectious disease specialists, cardiologists, cardiac surgeons, and microbiologists 2, 8
• Complex cases such as those involving rare pathogens, BCNIE, or multi-drug resistant organisms should be discussed by the Endocarditis Team 3, 10